AFC
VRTX icon

AFT Forsyth & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

AFT Forsyth & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,647
Closed -$389K – 159
2020
Q4 		$389K Sell
1,647
-4,460
-73% -$1.02M 0.24% 115
2020
Q3 		$895K Buy
6,107
+5,043
+474% +$1.39M 0.67% 50
2020
Q2 		$309K Buy
+1,064
New +$288K 0.26% 102

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AFT Forsyth & Company's VRTX Position: Q1 2021 in Review

AFT Forsyth & Company sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 1,647 shares — an estimated $389K sold.

AFT Forsyth & Company first reported a position in VRTX in Q2 2020 and held it in 3 quarters. The position peaked at $895K in Q3 2020. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • AFT Forsyth & Company reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • AFT Forsyth & Company sold 1,647 Vertex Pharmaceuticals shares in Q1 2021, an estimated $389K.
  • AFT Forsyth & Company first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • AFT Forsyth & Company's Vertex Pharmaceuticals position peaked at $895K in Q3 2020.
  • 1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on AFT Forsyth & Company's 13F filing for Q1 2021, filed 4 May 2021.